Friday, 10 May 2019

Atherectomy Devices Market Segmentation Detailed Study with Forecast Up To 2019

The global atherectomy devices market is projected to grow significantly over the forecast period. It is estimated that the global atherectomy devices market is expected to register a CAGR of 6.12% during the forecast period of 2018–2023, with an estimated market value of 1.09 billion in 2017. Atherectomy is a minimally invasive endovascular surgery technique. Atherectomy devices, such as catheters are used to remove atherosclerosis from the blood vessels.
The rising demand for minimally invasive technologies, coupled with the increase in the coronary and peripheral arterial diseases is expected to drive the growth of the market. Also, the high efficiency rate of the atherectomy devices is estimated to boost the growth of the intraocular lens market. According to the data published in 2015 by the Centers for Disease Control and Prevention (CDC), about 7,35,000 Americans have a heart attack annually. Factors such as post-operative complications, and lack of skilled medical professionals are limiting the growth of the market.
Moreover, major companies in the market are involved in new product launches to strengthen their position in the market. For instance, in June 2018, Biomerics, a medical device contract manufacturer announced the acquisition of FutureMatrix Interventional, Inc. The company aims to expand its portfolio of interventional catheters used in cardiovascular and urology fields, thus strengthening its position in the market.
Segmentation
The global atherectomy devices market is segmented on the basis of product type, application, and end user.
Based on application, the atherectomy devices market is segmented into cardiovascular, neurovascular, peripheral vascular, and others.
The atherectomy devices market, by product type is categorised into directional atherectomy systems, orbital atherectomy systems, photo-ablative (laser) atherectomy systems, rotational atherectomy systems, and others.
The directional atherectomy systems segment is expected to hold the largest share owing to the high treatment rate, whereas the photo-ablative (laser) atherectomy systems is expected to be the fastest growing segment owing to the growing preference by surgeons.
On the basis of end user, the market is segmented into hospitals, ambulatory surgery centers, and others.
On the basis of region, the global atherectomy devices market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and Latin America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, South Korea, and the rest of Asia-Pacific. The atherectomy devices market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Asia-Pacific was projected to be the fastest growing region for the global atherectomy devices market. This owes to the technological advancements resulting in the development of cost-effective atherectomy devices leading to high acceptance rate for the devices in the Asia-Pacific region. The Middle East and Africa holds the least share in the global atherectomy devices market due to the presence of economically diverse countries, and less initiatives taken by the government.
It is projected that the Americas dominated the global atherectomy devices market owing to the growth of the market in the North American region. This is largely attributed to the factors such as increase in research funding, and growing awareness about the high-end atherectomy devices among medical professionals. Europe is expected to hold the second largest share in the atherectomy devices market owing to growing healthcare infrastructure. Additionally, various initiatives by public and private organizations is anticipated to boost the growth of the atherectomy devices market.
Browse Complete 160 Pages Premium Research Report @ https://www.marketresearchfuture.com/reports/atherectomy-devices-market-7322

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Injectable Drug Delivery Devices Market Revenue, Opportunity, Forecast and Value Chain Analysis 2019

Market scenario:
Market Research Future (MRFR) in their latest report on the injectable drug delivery devices market claimed that the market could achieve such a feat. Injectable drug delivery devices are tools that helps in effective drug delivery into the body and creates an opportunity for the drug to work quickly.
The injectable drug delivery devices market is expected to receive substantial market traction due to the sleek designs and simplicity in application. Other than these factors, the market can gain more from rapidly increasing FDA approval of new products. Its being self-injectable is making it easier for several patients to take up these tools and keep their disease in check. These factors are for sure to trigger the global injectable drug delivery devices market.
The Global Injectable Drug Delivery Devices Market is to record 11.5% CAGR owing to its ease of application during the forecast period (2018-2023).
Competitive Landscape:
  • Antares Pharma,
  • AstraZeneca,
  • Eisai Co., Ltd.,
  • Becton,
  • Dickinson and Company,
  • Eli Lilly and Company,
  • Pfizer Inc.,
  • Hoffmann-La Roche AG,
  • Mylan N.V.,
  • Johnson & Johnson Services Inc.,
  • Novo Nordisk,
  • Novartis AG,
  • Teva Pharmaceutical Industries Ltd.,
  • Sanofi,
  • Inovio Pharmaceuticals Inc.
Segmental Analysis:
The Global Injectable Drug Delivery Devices Market has been segmented on the basis of devices, therapeutic application, usage pattern, site of delivery, distribution channel, facility of use, and region. Based on devices, the injectable drug delivery devices market has been segmented into conventional injection devices and self-injection devices. The conventional injection devices segment commands the major share of the global injectable drug delivery devices market and. The conventional injection devices segment has been sub-segmented into material, product, and utility. The self-injectable devices segment has been sub-segmented into needle-free injectors and pen systems and autoinjectors.
Based on therapeutic application, the market has been segmented into autoimmune diseases, hormonal disorders, cancer, and others. The autoimmune diseases segment is projecting dominance over the global injectable drug delivery devices market and is expected to reach the valuation of USD 19,913.7 Mn by the end of the review period. Based on usage pattern, the global injectable drug delivery devices market has been segmented into curative and immunization. The curative segment is expanding at the fastest growth rate in the global injectable drug delivery devices market during the assessment period.
Based on site of delivery, the injectable drug delivery devices market has been segmented into intramuscular, subcutaneous, and intradermal. The intramuscular segment commands the largest share of the global injectable drug delivery devices market. Based on distribution channel, the market has been segmented into hospital & retail pharmacies and online platforms. The hospitals & retail pharmacies segment is leading the global injectable drug delivery devices market. Whereas, the online platform segment is anticipated to expand at the fastest CAGR of 11.4% during the assessment period. Based on facility of use, the injectable drug delivery devices market has been segmented into hospitals and clinics, home care settings, and others.
Regional Analysis:
The global injectable drug delivery devices market, based on region, has been segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa. The market in the Americas is leading the global injectable drug delivery devices market and is anticipated to reach the valuation of USD 17,401.8 Mn by the end of the assessment period at the CAGR of 11.3%. Rapid expansion of biotechnological industry, increased prevalence of chronic diseases such as diabetes and cancer and high healthcare expenditure in the well-developed healthcare sector are majorly propelling the expansion of the injectable drug delivery devices market in this region.
Europe commanded for the second largest market share in the year 2017 and is anticipated to reach the valuation of USD 13,074.3 Mn by the end of the assessment period at a CAGR of 11.2%. Increased funding for R&D and easy adoption of technologically advanced healthcare solutions are fueling the expansion of the injectable drug delivery devices market in the Europe region. The Asia Pacific region is anticipated to register the fastest growth at a CAGR of 11.4% owing to the rising demand for therapeutics in the evolving healthcare sector in the emerging economies of this region. Lack of awareness and less exposure to primary healthcare services in the underdeveloped countries are leading to the slow growth of injectable drug delivery devices market in the Middle East and Africa region.
Browse Complete 80 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/injectable-drug-delivery-devices-market-1211
        
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Genetic Testing Market - Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2023

The Global Genetic Testing Market is expected to grow at CAGR of 11.50% to reach USD 22834.19 million till 2024. Some of the protuberant drivers supporting the growth of the global genetic testing market are identified as raising awareness about the benefits of genetic testing and the rising prevalence of genetic disorders.
Additionally, the role of genetic tests in forensic investigations and change in the trend of the genetic testing industry from service-driven to product-driven industry are expected to drive the global genetic testing market in the coming years.
Genetic testing is also known as DNA testing. Genetic tests involve a set of lab tests for the study of the genetic makeup of patients and identify any gene mutations and alterations in the healthy structure of DNA leading to the development of genetic disorders. Genetic testing offers a lot of benefits such as the chance for taking preventive measures to avoid potential diseases and lead a healthy life, knowledge about genetic alterations in the fetus that may lead to abnormal growth, and aids forensic investigations, among others. Due to the great benefits provided by these tests, people are getting more aware of them. This phenomenon intrigues people to go for tests to understand their genetic structure and possible disorders they may have to go through. The growing awareness has gathered a lot of audience for the genetic testing market and has also positively impacted the growth of this market.
Moreover, there has been tremendous growth in the prevalence of genetic disorders which may be due to various reasons such as geographical and environmental changes, change in food habits, pollution, and exposure to harmful radiations or chemicals. Genetic tests are also used to analyze family relations such as father, mother, half-brother, half-sister, and others. Forensic science and genetic testing have aided law and order to a great extent. With an increasing number of companies entering into this segment, the overall market for genetic tests has increased and expected to grow fast in the near future.
Segmentation                                                                                                                                        
Global genetic testing Market, by type, segmented into prescribed genetic testing and direct to consumer genetic testing. Prescribed genetic testing is the leading segment, which is growing at the highest CAGR to reach USD 21653.91 million by the end of 2024. Its large market share is majorly attributed to the widespread availability and service providers of various genetic tests and less availability of direct to consumer tests in all parts of the world.
Based on method, the genetic testing market is segmented into molecular genetic tests/ DNA tests, chromosomal genetic tests, and biochemical genetic tests. The molecular genetic test/DNA tests account for major share with 11.78% CAGR during the forecast period. Molecular testing helps to determine the sequence in DNA or RNA related to a particular disease.
The genetic testing market, by application, is segmented into reproductive health, cancer screening, ancestry, predictive and pre-symptomatic testing, and others. The reproductive health segment accounted for the largest market share of 33.61% in 2018.
Key Players
The prominent players in the global genetic testing market are Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), Illumina Inc. (US), Myriad Genetics, Inc. (US), PerkinElmer Inc. (US), QIAGEN N. V.  (Germany), Quest Diagnostics Incorporated (US), Eurofins Scientific (US), F. Hoffmann-La Roche Ltd (Switzerland), Blueprint Genetics (Finland), BGI Genomics (China), and Thermo Fisher Scientific Inc. (US).
Some of the key strategies followed by the players operating in the global genetic testing market were innovation, product development, acquisition, and expansion.
  • In April 2017, Myriad Genetics, Inc. signed an agreement with Clovis Oncology for the use of its FDA-Approved BRACAnalysis CDx Test to identify patients with germline BRCA Mutations for the Rubraca (rucaparib) treatment.
  • In January 2017, Bio-Rad Laboratories, Inc. announced the launch of the Single Cell Sequencing Solution in collaboration with Illumina Inc.
  • In August 2016, Abbott Laboratories launched Alinity, a family of next-generation system.
Regional Analysis         
The Americas accounted for the largest market share of the global genetic testing market, by region in 2018. This large share is majorly due to high awareness about genetic testing, high disposable income of the population, and implementation of newborn screening in the majority of the hospitals in the region. In 2015, approximately 12 million Americans suffered from genetic diseases which are approximately 1 in 20 people.
Europe accounted for the second largest market share. Technological advances, well-developed health care sector, and governmental support for the research and development of different tests and devices have provided fuel for the growth of the market. Germany commands the largest market share in the Europe genetic testing market.
Asia-Pacific is the fastest growing region for genetic testing. The presence of a huge patient population, rapid development in technology, and the presence of huge opportunities for the development of the market drive the growth of the Asia-Pacific genetic testing market. The Middle East & Africa accounted for the 8.8% market share in 2018.
Browse Complete 140 Pages Premium Research Report Enabled with 174 Respective Tables and Figures at @ https://www.marketresearchfuture.com/reports/genetic-testing-market-2009

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Thursday, 9 May 2019

Cardiac Tamponade Market Therapeutics in Global Markets to 2023 - Growth Driven by Increasing Uptake of Targeted Therapies and Rising Prevalence

Market Scenario
Cardiac Tamponade, is the build-up of fluid in the sac around the heart (pericardium) resulting in pressure and difficulty in compression of the heart which results in reduced blood volume to be pumped by the heart. The symptoms of cardiac tamponade include shortness of breath, weakness, light-headedness, cough, fatigue, swelling of the abdomen and veins in the arms or legs, or other areas, pale, blue or grey-tinted skin, rapid heartbeat, anxiety or restlessness, fainting etc. The causes of cardiac tamponade are cancer, kidney failure, chest trauma, pericarditis, connective tissue diseases, hypothyroidism, aortic rupture, post-operative consequences of cardiac surgery, tuberculosis etc. Cardiac tamponade can be life-threatening if not treated. Risk factors which increases the chances of cardiac tamponade include heart surgery, heart attack, injury to the heart, end-stage lung cancer, radiation therapy to the chest, hypothyroidism, systemic lupus erythematosus etc.
Diagnosis for this disorder is mostly based on x-ray, computed tomography (CT), Magnetic Resonance Imaging (MRI), coronary angiography, etc. The diagnosis may be further supported by ultrasound of the heart. Magnetic resonance imaging (MRI) is the diagnostic test of choice. The surgery segment is led by pericardiocentesis which involves drainage of the fluid by use of a needle. Cardiac tamponade occurs in approximately 2 per 10,000 individuals annually in the US alone.
The global cardiac tamponade market is expected to reach US$ 5.5 billion by 2023, and the market is projected to grow at a CAGR of ~ 5.5 % during the forecast period 2017-2023.
The market drivers for cardiac tamponade market are, increasing cardiac cases such as heart attack, cancer, kidney failure, end-stage lung cancer, hypothyroidism, rising screening and penetration of healthcare, growing awareness about cardiac diseases and growing income and healthcare expenditure etc. The market restraints are cost of cardiac tamponade surgery, complications and risk of the surgery along with invasive nature of this treatment.
Key Players
Some of key players profiled in the report are Boston Scientific Corporation, Medtronic, Inc., St. Jude Medical Inc., Hitachi, Ltd., Koninklijke Philips N.V., Siemens Healthcare Private Limited, Toshiba Medical Systems Corporation, General Electric Company, and others.
Segments:
The global cardiac tamponade market has been segmented on the basis of diagnosis, treatment, and end users.
Based on diagnosis, the market has been segmented as x-ray, computed tomography (CT), magnetic resonance imaging (MRI), coronary angiography, electrocardiogram (EKG) and others.
Based on the end users, the market has been segmented as hospitals & clinics, academic and research and others.
Based on treatment, the market has been segmented as surgery and drugs. The surgery segment has been sub-segmented as pericardiocentesis, thoracotomy and others. The drugs segment has been sub-segmented as antibiotics, blood volume expanders and others.
Regional Analysis
Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector during the forecast period.
The Americas account for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new drugs in the US drives the cardiac tamponade market. Also, concentration of major research companies in the developed countries of this region is adding fuel to the market growth. The large expenditure by the US on healthcare accounting to 16% of GDP also cruises the sale of cardiac tamponade treatment. The large number of specialized cardiac centres in the US also drives the market.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. The development of large hospitals such as the King Fahd hospital in Riyadh is driving the market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.
Europe is the second largest market in the world due to high income and healthcare penetration. Europe is led by countries such as Germany and France. UK is expected to be the fastest growing market.
Browse Complete 80 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/cardiac-tamponade-market-4341
         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Breast Biopsy Market Growth and Restrain Factors Analysis By 2023

Increased cancer detection rates globally have contributed to a rise in biopsy procedures. Market reports connected with the healthcare industry have been presented by Market Research Future which makes reports on other industry verticals that aims to analyze the current market scenarios better. The market is projected to develop at a favorable CAGR rate in the forecast period.
The prevalence of breast cancer has led to an increased level of reliance on breast biopsy procedures. Improved screening campaigns are also increasing the need for breast biopsy procedures. Furthermore, the rise in the awareness regarding cancer is anticipated to further motivate the expansion of the breast biopsy market in the forecast period.
Competitive Landscape
Significant reductions in administrative costs are inducing further expansion of the market. The vertical additions and product tactics of the market are boosting the potential of the market players. The development of a robust value chain is further motivating the development of the market. The strategic goals intended for the market are reinforced due to favorable product differentiation carried out by market competitors. The growth of the market is moving in a favorable direction due to new product launches or rising gross revenue of the players in the market. Increased adaptability of market players to new market trends and customers inclinations are lifting the growth curve of the market and will continue do so in the forecast period. The successful implementation of strategies is expected to motivate the market in the coming years.
The main players in the breast biopsy market globally are C.R. Bard Inc., NuVue Therapeutics, Argon Medical Devices, Inc., Devicor Medical Products Inc. Hologic Inc. Argon Medical Devices, Cook Medical Incorporated, Leica Biosystems, Encapsule Medical Devices LLC., Johnson & Johnson, Intact Medical Corporation, Becton, Dickinson and Company, Conceptus INC, Hologic Inc., Galini SRL, Karl Storz GmbH & Co. Kg, GE Healthcare.
Segmentation
The breast biopsy market has been carried out on the basis of guidance technology, technique type, product, and end-user. Based on product, the breast biopsy market has been segmented into biopsy tables, guidance systems, biopsy needles, biopsy wires, and others. The segmentation on the basis of technique type, the market is segmented into core needle biopsy, biopsy markers, fine needle aspiration biopsy, surgical biopsy, MRI-guided core needle biopsy, wire localization, and sentinel node biopsy. Additionally, the core needle biopsy segment is segmented into vacuum-assisted biopsy, ultrasound-guided core biopsy, stereotactic core needle biopsy, and freehand core-needle biopsy. The surgical biopsy is divided into excisional biopsy and incisional biopsy. Based on guidance technology, the breast biopsy market is segmented into mammography-guided magnetic resonance, CT-guided biopsy, ultrasound-guided, and other image-guided breast biopsy (thermography and PET). The end-user based segmentation of the market consists of ambulatory surgical centers, hospitals, diagnostic centers, among others. The regions that are a part of the breast biopsy market are Europe, Asia Pacific, Americas, and the Middle East and Africa.
Detailed Regional Analysis
The regional analysis of the breast biopsy market observes that the North American region is projected to account for the principal market share owing to the early implementation of sophisticated medical technologies and constant development by companies working in cancer diagnostics. The breast biopsy market is mainly focused on the North American and European regions, which is expected to account for more than 50% of the market portion. The European market is estimated to hold the next biggest market share as breast cancer is found to be most common in countries such as the UK and Belgium. The market share in the Asia Pacific region is also estimated to experience growth in the near future due to access to optimal treatment facilities, better adoption rate, growing demand for advanced technology, growing government initiatives, and rising healthcare costs. The market in the Middle Eastern and African region is projected to be responsible for the smallest share of the breast biopsy market owing to deficiency of technical knowledge, an underdeveloped healthcare sector, and meager medical facilities.

         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Palliative Care Market Value Share, Supply Demand, share and Value Chain 2019

Market Scenario 
Increasing incidence of diseases such as cancer, cardiovascular and infective disease are some of the drivers responsible for the market growth of global palliative care market. Other factors such as a growing number of palliative care centers worldwide, expanding aging demographics, increasing number of qualified physicians for palliative care are responsible for the rise in the global palliative market. The main object of palliative care is to enhance personal satisfaction for both the patient and family. This palliative care can be provided at any age and at any phase in a genuine ailment and can be furnished alongside remedial treatment.
Global Palliative Care market is expected to grow during the forecast period at a CAGR ~8.1 %.
Palliative care helps to improve the quality of life of patients and their families facing the problems of serious illness. The main focus of Palliative care is to provide relief from symptoms and stress of a serious illness. Their main goal is to improve the quality of life for both the patient and the family. Palliative care treats people living with a serious illness such as cancer, cardiac diseases such as congestive heath failure, kidney failure, Alzheimer’s and many more. It improves the quality of life of the patient and supports the primary physician, patient, and family. In last 15 years, the Palliative care market has a stunning growth and the factors that have led to the growth of this market are growing the aging population, increase in chronic life-threatening disease, initiative taken by the government and non- profit organization, and rise in government funding.  
However, the high cost of treatment, misuse of funding and lack of awareness are some of the factors which are hampering the growth of the market during the forecast period.
But the high cost of treatment, less private or public funding to hospital facilities and other medical centers can be a major restraint for the growth of the global palliative care market.
Key Players
  • Vitas Healthcare Corporation
  • Skilled Healthcare Group Incorporated
  • Sunrise Senior Living LLC
  • Kindred Healthcare Incorporated
  • Gentiva Health Services Incorporated
  • Home Instead Senior Care Incorporated
  • Amedisys Incorporated
  • Genesis HealthCare Corporation
Segmentation
The Global Palliative Care Market is segmented into types such as private residence care, hospice inpatient care, hospital inpatient care, nursing home and residential facility care and others. On the basis of application, the market is further segmented into cancer, cardiac diseases such as congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), kidney failure, Alzheimer’s, Parkinson’s, Amyotrophic Lateral Sclerosis (ALS) and many more. On basis of end-user, the market is further segmented into hospitals, home care settings, palliative care centers, long-term care centers & rehabilitation centers.
Regional Analysis
In terms of market value, North America will dominate the Palliative care market during the forecast period. Increasing incidences of life-threatening illness such as cancer, cardiovascular diseases, Alzheimer’s disease, kidney failure, chronic obstructive pulmonary disease and many more are some of the factors which are responsible for the growth of the market during the forecast period. In 2015 on average 90 % of US hospitals containing 300 beds or more provide Palliative care services to their patients. This has led to the growth of the market in coming years. The European market is expected to be the second-largest Palliative care market. The market growth in this region can be attributed to government funding and support of the healthcare sector coupled with increasing research and development. Moreover, a growing number of Palliative care centers worldwide, extending application for homecare, increasing number of qualified physicians for Palliative care center and expanding aging demographics are some of the factors responsible for the rise in the global Palliative care market. Asia-Pacific is expected to be the fastest-growing Palliative care market during the forecast period owing to the increasing prevalence of cardiac diseases, rising investments in healthcare, increasing geriatric population, and expansions by market players in the region. Asia-Pacific is giving the strong competition in the global Palliative care market by producing a cost-effective treatment that is high in demand in local as well as in the global market. The market in the Middle East and Africa is expected to account for the smallest share in the global Palliative care market due to the underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
The market has been segmented, by region, into the Americas, Europe, Asia Pacific, and the Middle East and Africa. The Global Palliative Care Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European Global Palliative Care Market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Global Palliative Care Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Palliative care market in the Middle East and Africa has been segmented into the Middle East and Africa.
Detailed Table Of Content
  1. Report Prologue
  2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
  1. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
  1. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
...TOC Continued!


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Mitochondrial Myopathies Market Expected to Grow at High Cagr during Forecast Period 2019 – 2023

Mitochondrial myopathy is a rare mutational disease and at present there is no treatment available for the disease. However, there are few diagnostic tests available in the market which are the only saving grace for the global mitochondrial myopathy diagnosis and treatment market at present. Research play a major role in the determining new diagnostic test and treatment options for mitochondrial myopathy.
Increasing number of patients with mitochondrial myopathy patients, development in the disease screening process and testing services, availability of incentives for research in rare genetic diseases, and government funding and support for the development of the treatment options. However, the unavailability of treatment for rare genetic diseases, and lack of awareness about the diagnosis of these diseases are major factors restraining the growth of the market. Additionally, large portion of the population are underdiagnosed due to lack of diagnostic methods also hinders the growth of the market.
The Mitochondrial Myopathies is expected to reach $ 600 million by the end of 2023, this market is projected to growing at a CAGR of ~ 3.2 % during 2017-2023.
Key players of Global Mitochondrial myopathies Market:
  • Reata Pharmaceuticals, Inc.
  • Stealth BioTherapeutics
  • Raptor Pharmaceutical Corp.
  • GeneDx
  • NeuroVive Pharmaceutical AB
Segments:
The global mitochondrial myopathies market is segmented on the basis of type and therapies. Based on type, the market has been segmented as Kearns-Sayre syndrome (KSS), Leigh syndrome, Mitochondrial DNA depletion syndrome (MDS), Mitochondrial encephalomyopathy, Mitochondrial neuro-gastrointestinal encephalomyopathy (MNGIE), Myoclonus epilepsy with ragged red fibers (MERRF), Neuropathy, ataxia and retinitis pigmentosa (NARP), Pearson syndrome, Progressive external ophthalmoplegia (PEO). Based on the therapies, the market has been segmented as dietary, supportive, vitamins, coenzymes and antioxidants and other.
Regional analysis
US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is the fastest region because of large unmet needs which is led by China and India. The Middle East and Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The poor regions of Africa are expected to be a laggard due to poor economic and political conditions.
Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/mitochondrial-myopathies-market-3684

         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Subscribe to: Posts (Atom)